Objective
The impact of the anti-depressant therapy on gonadal function has been
recognized and discussed over the years. However, data to supplement our
understanding of the impact of arjunolic acid (AA) therapies in protecting
against FXT-induced gonadal dysfunction is lacking clear scientific
evidence. Hence, this study aimed to investigate the possible effect of AA
on fluoxetine-induced altered testicular function in rats.
Methods
After 14 days acclimatization, Thirty-six (36) adult male rats were randomly
divided into 6 groups (n=6). Rats in groups 1 received normal saline
(10mL/kg); groups 2 & 3 were given AA (1.0mg/kg body weight) and AA
(2.0mg/kg body weight), respectively; whereas, rats in group 4 were given
FXT (10mg/kg/p.o/day), and groups 5 & 6 were given a combination of FXT
(10mg/kg) + AA (1.0mg/kg body weight); and FXT (10mg/kg) + AA (2.0mg/kg body
weight), respectively.
Results
The results shows that FXT significantly altered testicular steroidogenic
enzymes (3ß-HSD and 17ß-HSD) and proton pump ATPase (Na+/K+
ATPase, Ca
2
+
ATPase and H
+
ATPase)
activities, as well as testicular architecture when compared with controls.
More so, FXT caused oxido-inflammation and apoptosis, as evidence by
increases in MDA, MPO, TNF-α, IL-1ß, Caspase 3 and p53.
However, AA at a different dose significantly ameliorated the destructive
impacts of FXT on steroidogenic enzymes, proton pump ATPase as well as
increased Bcl-2, SOD, CAT, GSH and improved testicular architecture in
rats.
Conclusions
AA reverses fluoxetine-induced alterations in testicular steroidogenic
enzymes and membrane-bound ionic pump through suppression of
oxido-inflammatory stress and apoptosis.